Key clinical point: Fluid overload (FO) associated with increased administration of crystalloid fluids affected survival in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy. Weight-adjusted prescription of crystalloid fluids may reduce the risk for FO in this patient population.
Major finding: FO was observed in 12.3% of patients with AML. Patients receiving more than 100 mL crystalloid fluids/kg body weight were at a higher risk for FO (odds ratio, 2.78; P = .033). Patients with FO had inferior 90-day survival vs those without FO ( P = .0044).
Study details: Findings are from a retrospective analysis of 187 adult patients with AML receiving induction chemotherapy between 2014 and 2019.
Disclosures: Open Access funding was enabled and organized by Projekt DEAL. The authors declared no conflict of interests.
Source: Ballo O et al. Ann Hematol. 2021 Jul 25. doi: 10.1007/s00277-021-04593-x .